Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alnylam Pharmaceuticals (NQ: ALNY ) 237.83 +1.13 (+0.48%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alnylam Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > 3 Growth Stocks That Could Rocket Higher in 2023 January 06, 2023 Upcoming binary events could push these stocks to new all-time highs. Via The Motley Fool Alnylam Announces Updates to its Board of Directors January 05, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes December 21, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease October 07, 2022 Via Benzinga Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday December 16, 2022 Via Benzinga Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day December 15, 2022 From Alnylam Pharmaceuticals Via Business Wire Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis December 08, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Analyst Ratings for Alnylam Pharmaceuticals October 03, 2022 Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: Via Benzinga Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval October 03, 2022 Via Benzinga Alnylam to Webcast Virtual R&D Day December 08, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims December 06, 2022 Via Benzinga Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022 December 01, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Presentations at Upcoming November Investor Conferences November 09, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Looking Into Alnylam Pharmaceuticals's Return On Capital Employed November 02, 2022 Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter. Via Benzinga What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals November 02, 2022 Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: Via Benzinga Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year October 27, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program October 27, 2022 Via Benzinga Alnylam Pharmaceuticals: Q3 Earnings Insights October 27, 2022 Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Via Benzinga Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity October 27, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? October 20, 2022 Despite enthusiasm in some camps, the risk of potential cures clouds market projections. Via Investor's Business Daily Where Alnylam Pharmaceuticals Stands With Analysts October 13, 2022 Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: Via Benzinga Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company October 13, 2022 Via Benzinga Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results October 13, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire 3 Top Biotech Stocks Defying the Bear Market October 11, 2022 Bear market, shmear market. These biotech stocks are soaring despite the market downturn. Via The Motley Fool Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 October 06, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Where Alnylam Pharmaceuticals Stands With Analysts October 03, 2022 Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with... Via Benzinga What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals October 03, 2022 Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: Via Benzinga AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know October 02, 2022 Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... Via Benzinga Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting September 30, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.